Finance committee  Honourable Member Wallace, that's a very good question, and a very difficult question, as you know. I'm CEO of a company, and throughout my career in 17 years I've had to fire people, I've had to make very difficult decisions about resource allocation, which you as honourable mem

Finance committee  Honourable member, I don't have a specific number for you, but I can tell you that there are approximately 175 biotechnology companies in Canada that are focused on therapeutic development. Then there are others that are related to a variety of research in related fields, such as

Finance committee  Chairman, through you to the honourable member, the amount of capital required is significant. And having it based on market trends and having the market making the decision, we believe, is a more appropriate way to allocate funds. Of course, there are a number of organizations t

Finance committee  Mr. Chairman, honourable members, thank you for the opportunity to appear in front of your committee. My name is Anthony Giovinazzo and I am the CEO of a biotech company in Toronto that has a lead program in Parkinson's, applicable to worldwide markets. I am here today to plead